uniQure (NASDAQ:QURE) Shares Up 3.2% - Time to Buy?

Key Points

• uniQure's shares rose by 3.2% on Thursday, reaching a high of $15.48, despite a significant decline in trading volume.
• Wall Street analysts have shown **strong support** for uniQure, with several upgrades and price targets ranging between $28.00 and $70.00, translating to a consensus rating of "Moderate Buy."
• In its latest earnings report, uniQure beat expectations by reporting ($0.69) EPS and $5.26 million in revenue, despite a negative net margin of 1,387.98%.

uniQure N.V. (NASDAQ:QURE - Get Free Report)'s stock price rose 3.2% during mid-day trading on Thursday . The company traded as high as $15.48 and last traded at $15.07. Approximately 247,162 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 1,385,787 shares. The stock had previously closed at $14.60.

Analyst Ratings Changes

A number of brokerages have issued reports on QURE. Guggenheim reiterated a "buy" rating and set a $28.00 price target on shares of uniQure in a research report on Monday, May 12th. Chardan Capital lowered their target price on shares of uniQure from $38.00 to $35.00 and set a "buy" rating on the stock in a research note on Tuesday, July 29th. Mizuho raised shares of uniQure from a "neutral" rating to an "outperform" rating and set a $30.00 price target on the stock in a research note on Thursday, August 14th. Wall Street Zen raised shares of uniQure from a "sell" rating to a "hold" rating in a research note on Saturday, August 2nd. Finally, Cantor Fitzgerald set a $47.00 price target on uniQure in a report on Wednesday, July 30th. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $37.45.

uniQure Stock Performance

The stock's fifty day simple moving average is $14.58 and its 200-day simple moving average is $13.63. The company has a market capitalization of $841.16 million, a price-to-earnings ratio of -3.91 and a beta of 0.11. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53.

uniQure (NASDAQ:QURE - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, topping analysts' consensus estimates of ($0.89) by $0.20. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%.The business had revenue of $5.26 million during the quarter, compared to the consensus estimate of $5.00 million. Analysts predict that uniQure N.V. will post -3.75 EPS for the current year.

Insider Transactions at uniQure

In other news, Director Rachelle Suzanne Jacques sold 2,112 shares of the firm's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $30,518.40. Following the completion of the sale, the director owned 28,346 shares in the company, valued at approximately $409,599.70. This trade represents a 6.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Robert Gut sold 3,336 shares of the stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total value of $48,205.20. Following the transaction, the director directly owned 56,879 shares of the company's stock, valued at approximately $821,901.55. This trade represents a 5.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 22,144 shares of company stock worth $322,426 over the last 90 days. Company insiders own 4.79% of the company's stock.

Institutional Investors Weigh In On uniQure

Institutional investors and hedge funds have recently bought and sold shares of the stock. Main Management ETF Advisors LLC lifted its stake in shares of uniQure by 1.6% during the second quarter. Main Management ETF Advisors LLC now owns 56,420 shares of the biotechnology company's stock valued at $786,000 after buying an additional 912 shares during the period. Tudor Investment Corp ET AL lifted its position in uniQure by 5.9% during the 4th quarter. Tudor Investment Corp ET AL now owns 24,784 shares of the biotechnology company's stock worth $438,000 after acquiring an additional 1,371 shares in the last quarter. Wells Fargo & Company MN grew its holdings in uniQure by 13.9% during the 4th quarter. Wells Fargo & Company MN now owns 12,294 shares of the biotechnology company's stock valued at $217,000 after purchasing an additional 1,503 shares in the last quarter. Northern Trust Corp lifted its stake in shares of uniQure by 2.1% in the fourth quarter. Northern Trust Corp now owns 95,591 shares of the biotechnology company's stock worth $1,688,000 after acquiring an additional 1,923 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of uniQure by 6.0% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,978 shares of the biotechnology company's stock worth $1,253,000 after buying an additional 3,996 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company's stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.